Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.49 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18780748 | 0.89 | KDR (0.52) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18780744 | 0.89 | SCN9A (0.50) | KDRKITPDGFRA | |
| SCHEMBL18780743 | 0.85 | CDK2 (0.48) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18780745 | 0.82 | KDR (0.43) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4810259 | 0.82 | KDR (0.75) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17261173 | 0.82 | KDR (0.56) | KDR | |
| SCHEMBL18763343 | 0.81 | KDR (0.63) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13980535 | 0.81 | KDR (0.76) | KDR | |
| SCHEMBL17260998 | 0.80 | KDR (0.62) | KDRCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18780746 | 0.78 | AURKA (0.54) | KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057465-A1 | Inhibitors of Necroptosis | CATALYST THERAPEUTICS PTY LTD (AU) | 2018-03-01 | — | — | US | disclosed |
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | KDR 4376/4885CYP3A4 4866/4885CYP2D6 4870/4885 |
| US-20180057465-A1 | Inhibitors of Necroptosis | RIPK3, RIPK1, AIFM1 | KDR 4209/4885CYP3A4 4789/4885CYP2D6 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.